Clinical trial NCT03332940: Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
Official title: An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Nonalcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
Keywords: Tc99m-tilmanocept
Tilmanocept
NASH
Nonalcoholic Steatohepatitis
Lead sponsor: Navidea Biopharmaceuticals
Sponsor class: INDUSTRY
First posted: 2017-11-06
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization to the liver in subjects with and without moderate to severe nonalcoholic steatohepatitis (NASH) by planar and SPECT/CT imaging.

This study is designed to evaluate the safety and tolerability of Tc99m-tilmanocept in subjects with NASH.


Eligibility criteria: Inclusion Criteria:

* ALL SUBJECTS:

  1. The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.
  2. The subject is ≥18 years of age at the time of consent.
  3. The subject has a body mass index (BMI) between 18 and 45.

     CONTROL SUBJECTS:
  4. The subject is deemed to be clinically free of any infectious/inflammatory disease(s) for at least 4 weeks prior to the consent date.
  5. The subject has not taken any antibiotics for at least 4 weeks prior to the consent date.

NASH SUBJECTS:

4. The subject has biopsy-confirmed NASH within 12 months prior to enrollment. 5. The subject has a NAFLD Activity Score (NAS) of ≥ 4, with a score of at least 1 for each steatosis, lobular inflammation, and hepatocyte ballooning.

6. The subject has fibrosis staging of F3-F4.

Exclusion Criteria:

* ALL SUBJECTS:

  1. The subject is pregnant or lactating.
  2. The subject size or weight is not compatible with imaging per the investigator.
  3. The subject has received radiation therapy or chemotherapy or has a previous diagnosis of cancer other than basal cell carcinoma.
  4. The subject has renal insufficiency as demonstrated by a GFR of \< 60 mL/min.
  5. The subject has a chronic or persistent infection or has any condition that would, in the opinion of the examining physician, preclude their participation.
  6. The subject has a known allergy to or has had an adverse reaction to dextran exposure.
  7. The subject has received an investigational product within 30 days prior to the Tc 99m sulfur colloid administration.
  8. The subject has received any radiopharmaceutical within 7 days prior to the administration of Tc 99m sulfur colloid.
  9. The subject is HIV positive.
  10. The subject has a history of alcohol abuse or currently consumes alcohol in excess of 3 drinks/day for men or 2 drinks/day for women.
  11. The subject has hepatitis B or C.

      CONTROL SUBJECTS:
  12. The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase \[SGPT\]) or AST (aspartate aminotransferase \[SGOT\]) greater than two times the upper limit of normal (ULN).
  13. The subject has been diagnosed with NASH, NAFLD, or other chronic liver disease.
  14. The subject has been diagnosed with metabolic syndrome or Type I or II diabetes.

NASH SUBJECTS:

12. The subject has any chronic liver disease aside from NASH/NAFLD.

13. The subject has uncontrolled diabetes as indicated by an A1c \>9% within the 3 months prior to enrollment.

Primary outcomes:
measure: Adverse Drug Reaction
timeFrame: 5 days after Tc 99m tilmanocept injection
Secondary outcomes:
measure: Localization of Tc 99m tilmanocept
timeFrame: 5 days after Tc 99m tilmanocept injection
measure: Localization of Tc 99m sulfur colloid
timeFrame: 5 days after Tc 99m tilmanocept injection
measure: Localization Distribution Comparison
timeFrame: 5 days after Tc 99m tilmanocept injection
Other outcomes:
measure: Tc 99m tilmanocept Localization Distribution of SPECT/CT vs Elastography
timeFrame: 5 days after Tc 99m tilmanocept injection
measure: Tc 99m sulfur colloid Localization Distribution of SPECT/CT vs Elastography
timeFrame: 5 days after Tc 99m tilmanocept injection
Locations:
city: Kettering
country: United States
facility: Kettering Medical Center
state: Ohio
Study officials:
affiliation: Navidea Biopharmaceuticals, Inc.
name: Michael Blue, MD
role: STUDY_DIRECTOR
References:
citation: Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D, Blue M, Zhang J, Bracci P, Bshara W, Behr S, Maurer T, Williams K, Walker J, Beverly A, Blay B, Damughatla A, Larsen M, Mountain C, Neylon E, Parcel K, Raghuraman K, Ricks K, Rose L, Sivakumar A, Streck N, Wang B, Wasco C, Williams A, Schlesinger LS, Azad A, Rajaram MVS, Jarjour W, Young N, Rosol T, McGrath M. Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225]. Nucl Med Biol. 2016 Dec;43(12):837. doi: 10.1016/j.nucmedbio.2016.10.001. No abstract available.
citation: Cope, F.O., W. Metz, et al. Innovations in receptor-targeted precision imaging at Navidea: diagnosis up close and personal. Nature Outlook (31 October 2013); S125-S129.